Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avian Influenza
Broad-spectrum antiviral medicine inhibits bird flu virus by blocking attachment
November 18th, 2005
PRB Pharmaceuticals and Lee's Pharmaceuticals announced the discovery that v38 AMF-1 inhibits H5N1 infection by blocking the ability of the virus to attach to cells. Three fractions of v38 AMF-1 were tested against H5N1, the virus responsible for causing avian influenza (bird flu), and all showed excellent potency and selectivity at inhibiting H5N1 uptake and viral infections. The results come from the U.S. arm of an ongoing, multi-national, antiviral project jointly sponsored by PRB Pharmaceuticals and Lee's Pharmaceuticals. In the first arm of the project, researchers led by Dr. John Tam at the Chinese University of Hong Kong found v38 AMF-1 to be...
Source: Drug Week (2005-11-18)
|
